Tebu-bio negotiated exclusive distribution rights to Cellectis bioresearch’s cGPS® and cGPS® custom research kits for targeted gene integration in major European markets in which it has a presence. Cellectis will be responsible for design and production of the kits.

Previous articleEarly-Stage Investors Hedge Their Bets with Medical Devices
Next articleCubist to Buy Calixa for $92.5M to Pad Anti-Infective Pipeline